Skip Navigation



Brain Advance Access published online on November 16, 2008

Brain, doi:10.1093/brain/awn289
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
132/1/147    most recent
awn289v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hicks, D.
Right arrow Articles by Bushby, K. M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hicks, D.
Right arrow Articles by Bushby, K. M. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Cyclosporine A treatment for Ullrich congenital muscular dustrophy: a cellular study of mitochondrial dysfunction and its rescue

D. Hicks1, A. K. Lampe1, S. H. Laval1, V. Allamand2,3, C. Jimenez-Mallebrera4, M. C. Walter5, F. Muntoni4, S. Quijano-Roy6, P. Richard7, V. Straub1, H. Lochmüller1 and K. M. D. Bushby1

1Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK, 2INSERM, U582, Institut de Myologie, 3UPMC Univ Paris 06, UMR_S582, IFR14, Paris, France, 4Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, UK, 5Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Munich, Germany, 6Assistance Publique Hôpitaux de Paris, Service de Pédiatrie, Hôpital Raymond Poincaré, Garches and 7Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, UF Cardiogénétique et Myogénétique, Service de Biochimie Métabolique, Paris, France

Correspondence to: Prof. K Bushby, Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK E-mail: kate.bushby{at}ncl.ac.uk

Mutations in COL6A1, COL6A2 and COL6A3, the genes which encode the extra-cellular matrix component collagen VI, lead to Bethlem myopathy and Ullrich congenital muscular dystrophy (UCMD). Although the Col6a1–/– null mouse has an extremely mild neuromuscular phenotype, a mitochondrial defect has been demonstrated, linked to dysregulation of the mitochondrial permeability transition pore (PTP) opening. This finding has been replicated in UCMD muscle cells in culture, providing justification for a clinical trial using cyclosporine A, an inhibitor of PTP opening. We investigated whether PTP dysregulation could be detected in UCMD fibroblasts (the predominant source of muscle collagen VI), in myoblast cells from patients with other diseases and its response to rescue agents other than collagen VI. Although we confirm the presence of PTP dysregulation in muscle-derived cultures from two UCMD patients, fibroblasts from the same patients and the majority of fibroblasts from other well-characterized UCMD patients behave normally. PTP dysregulation is found in limb girdle muscular dystrophy (LGMD) type 2B myoblasts but not in myoblasts from patients with Bethlem myopathy, merosin-deficient congenital muscular dystrophy, LGMD2A, Duchenne muscular dystrophy and Leigh syndrome. In addition to rescue by cyclosporine A and collagen VI, this cellular phenotype was also rescued by other extra-cellular matrix constituents (laminin and collagen I). As the muscle derived cultures demonstrating PTP dysregulation shared poor growth in culture and lack of desmin labelling, we believe that PTP dysregulation may be a particular characteristic of the state of these cells in culture and is not specific to the collagen VI defect, and can in any case be rescued by a range of extra-cellular matrix components. Further work is needed on the relationship of PTP dysregulation with UCMD pathology.

Key Words: Muscular dystrophy; MPTP; extracellular matrix; Membrane Potential; mitochondria

Abbreviations: BM, Bethlem myopathy; CsA, cyclosporine A; ECM, extra-cellular matrix; LGMD, limb girdle muscular dystrophy; MDC1A, merosin-deficient congenital muscular dystrophy type 1A; PTP, permeability transition pore; TMRM, tetramethyl rhodamine methyl ester; UCMD, Ullrich congenital muscular dystrophy.

Received June 2, 2008. Revised September 9, 2008. Accepted October 8, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
V. K. Vishnudas and J. B. Miller
Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy
Hum. Mol. Genet., December 1, 2009; 18(23): 4467 - 4477.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Bernardi, P. Bonaldo, N. M. Maraldi, L. Merlini, and P. Sabatelli
On the pathogenesis of collagen VI muscular dystrophies--Comment on article of Hicks et al.
Brain, October 1, 2009; 132(10): e121 - e121.
[Full Text] [PDF]


Home page
BrainHome page
D. Hicks, A. Lampe, S. Laval, V. Allamand, C. Jimenez-Mallebrera, M. Walter, F. Muntoni, S. Quijano-Roy, P. Richard, V. Straub, et al.
Response to letter from Bernardi
Brain, October 1, 2009; 132(10): e122 - e122.
[Full Text] [PDF]


Home page
Hum Mol GenetHome page
E. Palma, T. Tiepolo, A. Angelin, P. Sabatelli, N. M. Maraldi, E. Basso, M. A. Forte, P. Bernardi, and P. Bonaldo
Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice
Hum. Mol. Genet., June 1, 2009; 18(11): 2024 - 2031.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.